Abbott Laboratories (ABT) Other Non-Current Liabilities (2009 - 2021)

Abbott Laboratories has reported Other Non-Current Liabilities for 13 years, with the latest figure at $3.7 billion in Q4 2021.

• Quarterly Other Non-Current Liabilities changed 0.03% year-over-year to $3.7 billion in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $3.7 billion (changed 0.03% YoY) and the FY2021 annual result came in at $3.7 billion, changed 0.03% from the prior year.
• Other Non-Current Liabilities steadied at $3.7 billion in Q4 2021 per ABT's latest filing, from $3.7 billion in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $4.9 billion in Q4 2017 and troughed at $3.7 billion in Q4 2020.
• A 5-year average of $4.0 billion and a median of $3.9 billion in 2019 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2017 and 2018: Other Non-Current Liabilities climbed 6.73% in 2017, then decreased 17.94% in 2018.
• Over 5 years, Other Non-Current Liabilities stood at $4.9 billion in 2017, then fell by 17.94% to $4.0 billion in 2018, then slipped by 1.0% to $3.9 billion in 2019, then declined by 6.59% to $3.7 billion in 2020, then climbed by 0.03% to $3.7 billion in 2021.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $3.7 billion, $3.7 billion, and $3.9 billion for Q4 2021, Q4 2020, and Q4 2019 respectively.